|  |  |  |
| --- | --- | --- |
| **Patients’ characteristics** | Clinical outcome at week 52 | p-value |
| Remission (n=24) | No remission (n=11) |
| Sex, male, n (%) | 13/24 (54) | 4/11 (36) | 0.328 |
| Crohn’s disease, n (%) | 15/24 (63) | 8/11 (73) | 0.709 |
| Paris classification for CD at diagnosisAge at diagnosis, n (%): A1a, A1bDisease location, n (%): L1, L2, L3Upper GI involvement, n (%): L4a, L4b Disease behaviour, n (%): B1, B2, B3Perianal disease modifier, n (%)Growth, n (%): G0, G1 | 6/15 (40), 9/15 (60)2/15 (13), 2/15 (13), 11/15 (73)12/15 (80), 1/15 (7)11/15 (73), 4/15 (27), 0/15 (0)1/15 (7)11/15 (73), 4/15 (27) | 4/8 (50), 4/8 (50)3/8 (38), 2/8 (25), 3/8 (38)3/8 (38), 1/8 (13)6/8 (75), 2/8 (25), 0/8 (0)1/8 (13)5/8 (63), 3/8 (38) | 0.6850.2330.8941.0001.0000.657 |
| Paris classification for UCDisease extent, n (%): E1, E2, E3, E4Disease severity, n (%): S0, S1 | 1/9 (11), 2/9 (22), 3/9 (33), 3/9 (33)7/9 (78), 2/9 (22) | 0/3 (0), 1/3 (33), 0/3 (0), 2/3 (67)2/3 (67), 1/3 (33) | 0.5631.000 |
| Age at diagnosis, year, median (IQR) | 12.3 (9.5-14.0) | 10.6 (7.5-11.8) | 0.107 |
| Disease duration prior to start IFX, months, median (IQR) | 6.5 (4.3-11.8) | 3.0 (2.0-9.0) | 0.099 |
| Concomitant immunosuppression at start of maintenance, n (%) | 17/24 (71) | 9/11 (82) | 0.685 |
| Concomitant immunosuppression at week 52, n (%) | 8/24 (33)  | 5/11 (45) | 0.708 |
| Start of maintenance infusion (week 14 or earlier), n (%) | 14/24 (58) | 7/11 (64) | 1.000 |

**Supplementary table 2:** Patients’ characteristics

**Footnotes:** CD: Crohn’s disease; GI: gastrointestinal tract; IFX: infliximab, IQR: interquartile range, n:number; PSC: primary sclerosing cholangitis; UC: ulcerative colitis